Macro-to-micro porous special bioactive glass and ceftriaxone-sulbactam composite drug delivery system for treatment of chronic osteomyelitis: An investigation through in vitro and in vivo animal trial

Journal of Materials Science: Materials in Medicine

Volumn 22, Issue 3, 2011, Pages 705-720

  Kundu, Biswanath ^a   Nandi, Samit Kumar ^b   Dasgupta, Sudip ^a   Datta, Someswar ^a   Mukherjee, Prasenjit ^b   Roy, Subhasis ^b   Singh, Aruna Kumari ^b   Mandal, Tapan Kumar ^b   Das, Partha ^b   Bhattacharya, Rupnarayan ^c   Basu, Debabrata ^a  

^a CSIR CENTRAL GLASS AND CERAMIC RESEARCH INSTITUTE   (India)

^b WEST BENGAL UNIVERSITY OF ANIMAL AND FISHERY SCIENCES   (India)

^c R G KAR MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ADSORPTION EFFICIENCY; ANIMAL MODEL; ANIMAL TRIALS; BIMODAL DISTRIBUTION; BONE FORMATION; DRUG CONCENTRATION; DRUG DELIVERY SYSTEM; DRUG ELUTION; FREEZE DRYING METHOD; GROUP-BASED; IMPLANT-BONE INTERFACE; IN-VITRO; IN-VIVO; INTERCONNECTIVITY; MICROPORES; POROUS BIOACTIVE GLASS; POROUS SCAFFOLD; S. AUREUS; SEM-EDAX; STAPHYLOCOCCUS AUREUS; VACUUM INFILTRATION;

ADSORPTION; ANIMALS; ANTIBIOTICS; BACTERIA; BONE; DRUG DELIVERY; ENZYME INHIBITION; RADIOLOGY; SCAFFOLDS; SCAFFOLDS (BIOLOGY);

BIOACTIVE GLASS;

ANTIBIOTIC AGENT; BIOACTIVE GLASS; CEFTRIAXONE; GLASS; MOLECULAR SCAFFOLD; PHOSPHATE BUFFERED SALINE; SULBACTAM; UNCLASSIFIED DRUG;

ADSORPTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBIOTIC THERAPY; ARTICLE; BODY FLUID; BONE; BONE MINERALIZATION; CHEMICAL COMPOSITION; CHRONIC OSTEOMYELITIS; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; ELUTION; ENERGY DISPERSIVE X RAY ANALYSIS; FREEZE DRYING; HISTOPATHOLOGY; HUMAN; IMPLANT; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; MINIMUM INHIBITORY CONCENTRATION; NANOFABRICATION; NONHUMAN; OSSIFICATION; PARTICLE SIZE; POROSITY; PRIORITY JOURNAL; RABBIT; RADIOLOGY; SCANNING ELECTRON MICROSCOPY; SIMULATED BODY FLUID; STAPHYLOCOCCUS AUREUS; X RAY ANALYSIS;

ADSORPTION; ANIMALS; ANTI-BACTERIAL AGENTS; BONE AND BONES; CEFTRIAXONE; CHRONIC DISEASE; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GLASS; HYDROGEN-ION CONCENTRATION; OSTEOMYELITIS; POROSITY; POWDERS; RABBITS; STAPHYLOCOCCUS AUREUS; SULBACTAM;

ANIMALIA; STAPHYLOCOCCUS AUREUS;

EID: 79958118284     PISSN: 09574530     EISSN: 15734838     Source Type: Journal    
DOI: 10.1007/s10856-010-4221-3     Document Type: Article

References (40)

1. Walenkamp GHIM. Chronic osteomyelitis. Acta Orthop Scand. 1997;68(5):497-506. (Pubitemid 27485120)
2. Mader JT, Landon GC, Calhoun J. Antimicrobial treatment of osteomyelitis. Clin Orthop Relat Res. 1993;295:87-95. (Pubitemid 23299634)
3. Kanellakopoulou K, Giamarellos-Bourboulis EJ. Carrier systems for the local delivery of antibiotics in bone infections. Drugs. 2000;59(6):1223-32. (Pubitemid 30410141)
4. Soundrapandian C, Datta S, Sa B. Drug-eluting implants for osteomyelitis. Crit Rev Ther Drug Carrier Syst. 2007;24(6):493-545. (Pubitemid 351234918)
5. Nandi SK, Mukherjee P, Roy S, Kundu B, De DK, Basu D. Local antibiotic delivery systems for the treatment of osteomyelitis - a review. Mater Sci Eng C. 2009;29(8):2478-85.
6. Giavaresi G, Borsari V, Fini M, Giardino R, Sambri V, Gaibani P, et al. Preliminary investigations on a new gentamicin and vancomycin- coated PMMA nail for the treatment of bone and intramedullary infections: an experimental study in the rabbit. J Orthop Res. 2008;26(6):785-92.
7. Kundu B, Soundrapandian C, Nandi SK, Mukherjee P, Dandapat N, Roy S, et al. development of new localized drug delivery system based on ceftriaxone-sulbactam composite drug impregnated porous hydroxyapatite: a systematic approach for in vitro and in vivo animal trial. Pharm Res. 2010;27(8):1659-76.
8. Nandi SK, Kundu B, Ghosh SK, Mandal TK, Datta S, De DK, et al. Cefuroxime-impregnated calcium phosphates as an implantable delivery system in experimental osteomyelitis. Ceram Int. 2009;35(4):1367-76.
9. Hing KA. Bioceramic bone graft substitutes: influence of porosity and chemistry. Int J Appl Ceram Technol. 2005;2(3):184-99. (Pubitemid 40951789)
10. Mader JT, Shirtliff ME, Bergquist SC, Calhoun J. Antimicrobial treatment of chronic osteomyelitis. Clin Orthop Relat Res. 1999;360:47-65. (Pubitemid 29140934)
11. Nandi SK, Kundu B, Datta S, De DK, Basu D. The repair of segmental bone defects with porous bioglass: an experimental study in goat. Res Vet Sci. 2009;86(1):162-73.
12. Bharati S, Soundrapandian C, Basu D, Datta S. Studies on a novel bioactive glass and composite coating with hydroxyapatite on titanium based alloys: effect of γ-sterilization on coating. J Eur Ceram Soc. 2009;29(12):2527-35.
13. Caron F, Gutmann L, Bure A, Pangon B, Vallois JM, Pechinot A, et al. Ceftriaxone-sulbactam combination in rabbit endocarditis caused by a strain of Klebsiella pneumoniae producing extended-broad-spectrum TEM-3 beta-lactamase. Antimicrob Agents Chemother. 1990;34(11):2070-4. (Pubitemid 20373835)
14. Foulds G, Stankewich JP, Marshall DC, O'Brien MM, Hayes SL, Weidler DJ, et al. Pharmacokinetics of sulbactam in humans. Antimicrob Agents Chemother. 1983;23(5):692-9. (Pubitemid 13087004)
15. Ghosh SK, Nandi SK, Kundu B, Datta S, De DK, Roy SK, et al. In vivo response of porous hydroxyapatite and beta-tricalcium phosphate prepared by aqueous solution combustion method and comparison with bioglass scaffolds. J Biomed Mater Res. 2008;86(1):217-27. (Pubitemid 351874386)
16. Kundu B, Sinha MK, Mitra MK, Basu D. Fabrication and characterization of porous hydroxyapatite ocular implant followed by an in vivo study in dogs. Bull Mater Sci. 2004;27(2):133-40.
17. Hench LL. The story of Bioglass̄. J Mater Sci: Mater Med. 2006; 17(11):967-78.
18. Hasegawa M, Sudo A, Komlev VS, Barinov SM, Uchida A. High release of antibiotic from a novel hydroxyapatite with bimodal pore size distribution. J Biomed Mater Res. 2004;70(2):332-9. (Pubitemid 39006912)
19. Kokubo T, Kushitani H, Sakka S, Kitsugi T, Yamamuro T. Solutions able to reproduce in vivo surface-structure changes in bioactive glass-ceramic A-W. J Biomed Mater Res. 1990;24(6):721-34. (Pubitemid 20236523)
20. Norden CW. Experimental osteomyelitis. I. A description of the model. J Infect Dis. 1970;122(5):410-8.
21. Jones JR, Ehrenfried LM, Hench LL. Optimising bioactive glass scaffolds for bone tissue engineering. Biomaterials. 2006;27(7):964-73. (Pubitemid 41566688)
22. Gibson LJ, Ashby MF. Cellular solids: structure and properties. 2nd ed. Cambridge: Cambridge University Press; 1997.
23. D883-99. Standard terminology relating to plastics. American Standard for Testing and Methods. ASTM; 1999.
24. Zhu Y, Kaskel S. Comparison of the in vitro bioactivity and drug release property of mesoporous bioactive glasses (MBGs) and bioactive glasses (BGs) scaffolds. Microporous Mesoporous Mater. 2009;118(1-3):176-82.
25. Komlev VS, Barinov SM, Koplik EV. A method to fabricate porous spherical hydroxyapatite granules intended for time-controlled drug release. Biomaterials. 2002;23(16):3449-54. (Pubitemid 34615651)
26. Zhao YF, Loo SC, Chen YZ, Boey FY, Ma J. In situ SAXRD study of sol-gel induced well-ordered mesoporous bioglasses for drug delivery. J Biomed Mater Res A. 2008;85(4):1032-42. (Pubitemid 351717972)
27. Burgos AE, Belchior JC, Sinisterra RD. Controlled release of rhodium (II) carboxylates and their association complexes with cyclodextrins from hydroxyapatite matrix. Biomaterials. 2002;23(12):2519-26. (Pubitemid 34292443)
28. Hench LL. Bioceramics: from concept to clinic. J Am Ceram Soc. 1991;74(7):1487-510.
29. Rai B, Teoh SH, Ho KH. An in vitro evaluation of PCL-TCP composites as delivery systems for platelet-rich plasma. J Control Release. 2005;107(2):330-42. (Pubitemid 41316295)
30. Itokazu M, Ohno T, Tanemori T, Wada E, Kato N, Watanabe K. Antibiotic-loaded hydroxyapatite blocks in the treatment of experimental osteomyelitis in rats. J Med Microbiol. 1997;46(9):779-83. (Pubitemid 27376780)
31. Korkusuz F, Korkusuz P, Eksioglu F, Gursel I, Hasirci V. In vivo response to biodegradable controlled antibiotic release systems. J Biomed Mater Res. 2001;55(2):217-28. (Pubitemid 32198504)
32. Sanchez E, Baro M, Soriano I, Perera A, Evora C. In vivo-in vitro study of biodegradable and osteointegrable gentamicin bone implants. Eur J Pharm Biopharm. 2001;52(2):151-8. (Pubitemid 32755893)
33. Joosten U, Joist A, Frebel T, Brandt B, Diederichs S, von Eiff C. Evaluation of an in situ setting injectable calcium phosphate as a new carrier material for gentamicin in the treatment of chronic osteomyelitis: studies in vitro and in vivo. Biomaterials. 2004;25(18):4287-95. (Pubitemid 38388590)
34. Woodward JC, Riser WH. Morphology of fracture non union and osteomyelitis. Vet Clin North Am Small Anim Pract. 1991;21:313-44.
35. Barza M. Anatomical barriers for antimicrobial agents. Eur J Clin Microbiol Infect Dis. 1993;12(Suppl 1):31-5.
36. Gordon L, Chiu EJ. Treatment of infected non-unions and segmental defects of the tibia with staged microvascular muscle transplantation and bone-grafting. J Bone Joint Surg. 1988;70(3):377-86.
37. Calhoun J, Mader JT. Antibiotic beads in the management of surgical infections. Am J Surg. 1989;157(4):443-9. (Pubitemid 19100960)
38. Walenkamp GHIM, Vree TB, Van Rens TJG. Gentamicin-PMMA beads: pharmacokinetic and nephrotoxicological study. Clin Orthop Relat Res. 1986;205:171-83. (Pubitemid 16011268)
39. Shrivastava SM, Saurabh S, Rai D, Dwivedi VK, Chaudhary M. In vitro microbial efficacy of sulbactomax: a novel fixed dose combination of ceftriaxone sulbactam and ceftriaxone alone. Curr Drug Ther. 2009;4(1):73-7.
40. Castro C, Sanchez E, Delgado A, Soriano I, Nunez P, Baro M, et al. Ciprofloxacin implants for bone infection. In vitro-in vivo characterization. J Control Release. 2003;93(3):341-54. (Pubitemid 37485956)